Gebauer keratome gets FDA approval

Article

The Gebauer SL Keratome, a sterile single-use instrument for performing Epi-LASIK and LASIK surgeries, has received FDA clearance and can now be distributed for sale in the US.

The SL Keratome, a sterile single-use instrument for performing Epi-LASIK and LASIK surgeries, has received FDA clearance and can now be distributed for sale in the US.

As it is a single-use product, the SL Keratome does not require repeated cleaning, which reduces cycle times and provides a more convenient option for the surgeon. The easy-to-use ergonomic design features a simple foot pedal control as well as a "Click And Go" set-up. In addition, the handpiece of the SL does not need to be moved during surgery, allowing the surgeon to perform epithelial separations as well as LASIK surgery.

The SL Keratome received CE mark approval in August 2008.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.